Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study

View ORCID ProfileMichael Marks, Pere Millat, Dan Ouchi, View ORCID ProfileChrissy Roberts, Andrea Alemany, Marc Corbacho-Monné, Maria Ubals, Martí Vall-Mayans, Camila G-Beiras, Nuria Prat, Jordi Ara, Bonaventura Clotet, Oriol Mitjà
doi: https://doi.org/10.1101/2020.10.27.20220277
Michael Marks
1London School of Hygiene and Tropical Medicine, London, United Kingdom
2Hospital for Tropical Diseases, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Marks
  • For correspondence: michael.marks@lshtm.ac.uk
Pere Millat
3Barcelona Institute for Global Health – University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Ouchi
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chrissy Roberts
1London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chrissy Roberts
Andrea Alemany
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Corbacho-Monné
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Ubals
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martí Vall-Mayans
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
5Hospital Universitari Germans Trias i Pujol, Badalona Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camila G-Beiras
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuria Prat
5Hospital Universitari Germans Trias i Pujol, Badalona Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Ara
5Hospital Universitari Germans Trias i Pujol, Badalona Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bonaventura Clotet
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
5Hospital Universitari Germans Trias i Pujol, Badalona Spain
6Universitat de Vic – Universtiat Central de Catalunya, Vic, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oriol Mitjà
4Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
5Hospital Universitari Germans Trias i Pujol, Badalona Spain
6Universitat de Vic – Universtiat Central de Catalunya, Vic, Spain
7Lihir Medical Centre-InternationalSOS, Lihir Island, Papua New Guinea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background There remains limited data on what variables affect the risk of transmission of SARS-CoV-2 and developing symptomatic Covid-19 and in particular the relationship to viral load (VL).

Methods We analysed data collected in a trial of hydroxychloroquine post-exposure prophylaxis. Covid-19 cases and their contacts were identified through the local epidemiological surveillance system. VL, estimated by quantitative PCR, was assessed at enrollment, at day 14, and whenever the participant reported Covid-19-like symptoms. Risk of transmission, risk of developing symptomatic disease and incubation dynamics were evaluated using random-effects regression analysis.

Findings We identified 314 cases, 282 of which had at least one contact (753 contacts in total). Ninety (33%) of 282 clusters had at least one transmission event. The secondary attack rate was 16% (125/753), with a variation from 12% to 24% for VL of the index case of <106, and >109 copies/mL, respectively (OR per log10 increase in VL 1.3 95%CI 1.1–1.6). Increased risk of transmission was also associated with household contact (OR 2.7; 1.4–5.06) and age of the contact (OR 1.02; 1.01–1.04). The proportion of PCR positive contacts who developed symptomatic Covid-19 was 40.3% (181/449), with a variation from 25% to 60% for VL of the contact <107, and >109 copies/mL (HR log10 increase in VL 1.12; 95% CI 1.05 – 1.2). Time to onset of symptomatic disease decreased from a median of 7 days (IQR 5–10) for individuals with an initial viral load <107 to 6 days (4–8) and 5 days (3–8) for individuals with an initial viral load of 107–109 and >109, respectively.

Interpretation We show that the viral load of the index case is a leading driver of SARS-CoV-2 transmission. The risk of symptomatic Covid-19 is strongly associated with viral load of the contact at baseline, which shortens the incubation time in a dose-dependent manner.

Funding Crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), and Generalitat de Catalunya.

Evidence before this study In September 2020, we searched PubMed database for articles reporting on factors influencing transmission and the risk of developing symptomatic disease. Search terms included “Covid-19”, “transmission”, “incubation time”, and “risk”, with no language restrictions. By the time of performing this search, various authors had reported on retrospective analyses of clusters of index cases and their corresponding contacts, as well as series of patients who developed symptomatic Covid-19 disease after PCR positive result. Besides describing the secondary attack rate, various authors identified risk factors for transmission associated with the place and duration of exposure and the lack of use of personal protective equipment. However, we found no clear evidence regarding the influence of the characteristics of the index case on transmission risk. Similarly, although various retrospective series of patients with positive PCR results had reported incubation times elsewhere, the characteristics of index case and contacts that may influence the risk of developing symptomatic Covid-19 and the time to this event had been barely addressed.

Added value of this study We analyzed data from a large cluster-randomized clinical trial on post-exposure therapy for Covid-19 that provide new information on SARS-CoV-2 transmission dynamics. Several design components add value to this dataset. Notably, quantitative PCR was available for the index cases to estimate risk of transmission. Furthermore, quantitative PCR was also performed on asymptomatic contacts at the time of enrollment allowing to investigate the dynamics of symptomatic disease onset among them. We found that the viral load of the index case was the leading determinant of the risk of SARS-CoV-2 PCR positivity among contacts. Among contacts who were SARS-CoV-2 PCR positive at baseline, viral load significantly influenced the risk of developing the symptomatic disease in a dose-dependent manner. This influence also became apparent in the incubation time, which shortened with increasing baseline viral loads.

Implication of all the available evidence Our results provide important insights into the knowldge regarding the risk of SARS-CoV-2 transmission and Covid-19 development. The fact that the transmission risk is primarily driven by the viral load of index cases, more than other factors such as their symptoms or age, suggests that all cases should be considered potential transmitters irrespective of their presentation and encourages assessing viral load in cases with a larger number of close contacts. Similarly, our results regarding the risk and expected time to developing symptomatic Covid-19 encourage risk stratification of newly diagnosed SARS-CoV-2 infections based on the initial viral load.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), and Generalitat de Catalunya.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research was approevd by the Ethics Committee of the Germans Trias i Pujol Hospital (Badalona, Spain)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data referred to in the manuscript are available upon request to the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study
Michael Marks, Pere Millat, Dan Ouchi, Chrissy Roberts, Andrea Alemany, Marc Corbacho-Monné, Maria Ubals, Martí Vall-Mayans, Camila G-Beiras, Nuria Prat, Jordi Ara, Bonaventura Clotet, Oriol Mitjà
medRxiv 2020.10.27.20220277; doi: https://doi.org/10.1101/2020.10.27.20220277
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study
Michael Marks, Pere Millat, Dan Ouchi, Chrissy Roberts, Andrea Alemany, Marc Corbacho-Monné, Maria Ubals, Martí Vall-Mayans, Camila G-Beiras, Nuria Prat, Jordi Ara, Bonaventura Clotet, Oriol Mitjà
medRxiv 2020.10.27.20220277; doi: https://doi.org/10.1101/2020.10.27.20220277

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5199)
  • Forensic Medicine (3)
  • Gastroenterology (193)
  • Genetic and Genomic Medicine (746)
  • Geriatric Medicine (76)
  • Health Economics (211)
  • Health Informatics (690)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5793)
  • Intensive Care and Critical Care Medicine (355)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (135)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1986)
  • Radiology and Imaging (342)
  • Rehabilitation Medicine and Physical Therapy (154)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)